Eiger BioPharmaceuticals, Inc.
EIGR
Kedudukan dalam Saham
#36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Harga Saham
$1.73
Disegerakkan terakhir: 2025-06-17
Modal Pasaran
$2.55M
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-79.71%
Negara
US
Perdagangan Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Bilangan saham terbitan bagi Eiger BioPharmaceuticals, Inc. (EIGR)
Bilangan saham terbitan setakat December 2023: 1.48M
Menurut laporan kewangan terkini dan harga saham Eiger BioPharmaceuticals, Inc., bilangan saham terbitan semasa ialah 1.48M. Pada akhir December 2022, syarikat mempunyai 1.39M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Eiger BioPharmaceuticals, Inc. (EIGR) dari 2016 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 1.48M | 0.22% |
| 2023 | 1.48M | 6.39% |
| 2022 | 1.39M | 22.64% |
| 2021 | 1.13M | 20.61% |
| 2020 | 938.11K | 23.51% |
| 2019 | 759.52K | 66.18% |
| 2018 | 457.03K | 57.09% |
| 2017 | 290.93K | 45.30% |
| 2016 | 200.23K | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 17,061.24% |
US
|
|
| 396.00M | 26,665.85% |
US
|
|
| 478.91M | 32,269.92% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 4,103.15% |
NL
|